Back to top
more

Aurinia Pharmaceuticals (AUPH)

(Delayed Data from NSDQ)

$4.81 USD

4.81
2,097,931

-0.10 (-2.04%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $4.81 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AUPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Aurinia Pharmaceuticals Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 350 389 466 398 306
Receivables 24 13 15 1 0
Notes Receivable 0 0 0 0 0
Inventories 40 25 19 14 0
Other Current Assets 11 15 13 6 9
Total Current Assets 425 443 513 419 315
Net Property & Equipment 3 4 4 5 0
Investments & Advances 0 0 0 24 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 5 6 8 9 11
Deposits & Other Assets 2 13 12 0 0
Total Assets 548 471 543 464 327
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 54 40 35 25 11
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 15 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 7 5 5 6 0
Total Current Liabilities 77 46 41 32 11
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 75 0 0 0 0
Other Non-Current Liabilities 11 12 16 16 42
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 170 65 64 56 53
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1,200 1,185 1,177 944 790
Capital Surplus 121 85 59 39 24
Retained Earnings -942 -864 -756 -575 -540
Other Equity -1 -1 -1 -1 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 378 405 479 408 274
Total Liabilities & Shareholder's Equity 548 471 543 464 327
Total Common Equity 378 405 479 408 274
Shares Outstanding 143.60 142.20 129.60 126.70 111.80
Book Value Per Share 2.63 2.85 3.70 3.22 2.45

Fiscal Year End for Aurinia Pharmaceuticals Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 350 338 351 362
Receivables NA 24 38 20 19
Notes Receivable NA 0 0 0 0
Inventories NA 40 33 33 32
Other Current Assets NA 11 18 13 11
Total Current Assets NA 425 426 416 424
Net Property & Equipment NA 3 4 4 4
Investments & Advances NA 0 1 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 5 5 6 6
Deposits & Other Assets NA 2 2 2 13
Total Assets NA 548 555 549 452
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 54 52 41 36
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 15 13 14 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 7 7 5 5
Total Current Liabilities NA 77 74 62 42
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 75 72 79 0
Other Non-Current Liabilities NA 10 9 12
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 170 163 157 61
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1,200 1,199 1,196 1,193
Capital Surplus NA 121 110 99 89
Retained Earnings NA -942 -915 -902 -891
Other Equity NA -1 -1 -1 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 378 392 392 390
Total Liabilities & Shareholder's Equity NA 548 555 549 452
Total Common Equity 0 378 392 392 390
Shares Outstanding 144.60 143.60 143.60 143.30 143.00
Book Value Per Share 0.00 2.63 2.73 2.74 2.73